Effects of PVC bags sterilization process on the 5-fluorouracil stability

Biomaterials

Volumn 20, Issue 7, 1999, Pages 655-661

  Dine, T ^a   Kahlfi, F ^a   Duban, M ^a   Gressier, B ^b   Luyckx, M ^a   Brunet, C ^a   Meersseman, X ^a   Goudaliez, F ^c   Cazin, M ^a   Cazin, J C ^a  

^a UNIV LILLE   (France)

^b Service de Radiotherapie   (France)

^c Laboratoires Macopharma   (France)

Author keywords

5 FU; HPLC; pH; PVC bag; Stability; Sterilization process

Indexed keywords

BIOCOMPATIBILITY; DRUG THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH EFFECTS; POLYVINYL CHLORIDES; PRECIPITATION (CHEMICAL); SODIUM CHLORIDE; STERILIZATION (CLEANING);

EVAPORATIVE WATER LOSS; FLUOROURACIL STABILITY; INFUSION BAGS;

BIOMATERIALS;

FLUOROURACIL; HYDROCHLORIC ACID; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PLASTICIZER; POLYVINYLCHLORIDE; SODIUM CHLORIDE;

ARTICLE; BETA RADIATION; CHEMICAL REACTION; COLOR; CONTROLLED STUDY; DILUTION; DRUG STORAGE; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; PRECIPITATION; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; BETA RAYS; BIOCOMPATIBLE MATERIALS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETHYLHEXYL PHTHALATE; DRUG STABILITY; FLUOROURACIL; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; PLASTICIZERS; POLYVINYL CHLORIDE; SOLUTIONS; STERILIZATION;

EID: 0033120685     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(98)00221-X     Document Type: Article

References (21)

1. [1] Curreri A, Ansfield F, McIver F, Waisman HA, Heidelberger C. Clinical studies with 5-FU. Cancer Res 1985;18:478-84.
2. [2] Chang AYC, Most C, Pandya KJ. Continuous intravenous infusion of 5-FU in the treatment of refractory breast cancer. Am J Clin Oncol 1989;12:453-5.
3. [3] Fraile RJ, Baker LH, Buroker TR, Horwitz T, Vaitkevicius VK. Pharmacokinetics of 5-FU administered orally by rapid intravenous and by slow infusion. Cancer Res 1980;40:2223-8.
4. [4] Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius V. Low-dose continuous infusion 5-FU: evaluation in advanced breast cancer. Cancer 1989;63:419-22.
5. [5] Cameron DA, Gabra H, Leonard RCF. Continuous 5-FU in the treatment of breast cancer. Br J Cancer 1994;70:120-4.
6. [6] Raymond E, Palangie T, Jouve M et al. Protracted continuous infusion of 5-FU in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer. Cancer Invest 1996;14:91-7.
7. [7] Spicer DV, Ardalan N, Daniels JR, Silberman H, Johnson K. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-FU with pharmacokinetics. Cancer Res 1988;48:459-61.
8. [8] Kowaluk EA, Roberts MS, Blackburn HD et al. Interactions between drugs and polyvinylchloride infusion bags. Am J Hosp Pharm 1981;38:1308-13.
9. [9] Faouzi MA, Dine T, Luyckx M et al. Leaching of diethylhexyl phthalate from PVC bags into intravenous teniposide solution. Int J Pharm 1994;105:89-93.
10. [10] Waugh NW, Trissel LA, Stella VJ. Stability, compatibility and plasticizer extraction of Taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991;48:1520-4.
11. [11] Farhang-Asnafi S, Callaert S, Barre J, Tillement JP, Thebault A. Influence du solvant de dilution sur la stabilité de la nouvelle forme de 5-FU en perfusion. J Pharm Clin 1997;16:45-8.
12. [12] Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. Long-term stability of 5-FU stored in PVC bags and in ambulatory pump reservoirs. J Pharm Biomed Anal 1996;14:395-9.
13. [13] Milano G, Renée N. Etude de compatibilité physicochimique 5-FU (nouvelle préparation française)-acide folinique. Bull Cancer 1995;82:189-95.
14. [14] Quebbeman EJ, Hamid AAR, Hoffman NE, Ausman RK. Stability of fluorouracil in plastic containers for continuous infusion at home. Am J Hosp Pharm 1984;41:1153-6.
15. [15] Stiles ML, Allen LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. Am J Hosp Pharm 1989;46:2036-40.
16. [16] Barberi-Heyob M, Watelet M, Merlin JL, Bléger C, Schroeder B. Stabilité des préparations de 5-FU en fonction de différents paramètres. Bull Cancer 1985;82:1025-31.
17. [17] Rochard EB, Barthes DMC, Courtois PY. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs. Am J Hosp Pharm 1992;49:619-23.
18. [18] Yagoubi N, Baillet A, Pellerin F, Ferrier D. Physico-chemical behaviour of β-irradiated plastic materials currently used as packagings and medical products. Nucl Instrum Meth B 1995;105:340-4.
19. [19] Winberg LD, Badr MZ. Mechanism of phthalate-induced inhibition of hepatic mitochondrial β-oxidation. Toxicol Letters 1995;76:63-9.
20. [20] Gibson TP, Briggs WA, Boone BJ. Delivery of di-2-ethylhexyl phthalate to patients during hemodialysis. J Lab Clin Med 1976;87:519-24.
21. [21] Nässberger L, Arbin A, Östelius J. Exposure of patients to phthalates from polyvinyl chloride tubes and bags during dialysis. Nephron 1987;45:286-90.